American Century Companies’s Celldex Therapeutics CLDX Stock Holding History

American Century Companies’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.8M	Buy	1,042,395 +186,085	+22%	+$6.01M	0.02%	972
2026 Q1	$27.2M	Buy	856,310 +1,084	+0.1%	+$29.6K	0.01%	1039
2025 Q4	$23.2M	Buy	855,226 +39,666	+5%	+$1.04M	0.01%	1096
2025 Q3	$21.1M	Buy	815,560 +35,575	+5%	+$824K	0.01%	1125
2025 Q2	$15.9M	Buy	779,985 +154,664	+25%	+$3.01M	0.01%	1190
2025 Q1	$11.3M	Buy	625,321 +16,864	+3%	+$377K	0.01%	1280
2024 Q4	$15.4M	Buy	608,457 +193,093	+46%	+$5.25M	0.01%	1174
2024 Q3	$14.1M	Sell	415,364 -636	-0.2%	-$24.2K	0.01%	1174
2024 Q2	$15.4M	Buy	416,000 +233,928	+128%	+$8.83M	0.01%	1063
2024 Q1	$7.64M	Buy	182,072 +21,021	+13%	+$863K	﹤0.01%	1315
2023 Q4	$6.39M	Buy	161,051 +191	+0.1%	+$5.62K	﹤0.01%	1322
2023 Q3	$4.43M	Buy	160,860 +23	+0%	+$721	﹤0.01%	1375
2023 Q2	$5.46M	Sell	160,837 -4,891	-3%	-$165K	﹤0.01%	1272
2023 Q1	$5.95M	Sell	165,728 -32,233	-16%	-$1.39M	﹤0.01%	1199
2022 Q4	$8.82M	Buy	197,961 +2,399	+1%	+$85.6K	0.01%	1018
2022 Q3	$5.5M	Sell	195,562 -723	-0.4%	-$22.2K	﹤0.01%	1078
2022 Q2	$5.29M	Buy	196,285 +13,268	+7%	+$385K	﹤0.01%	1099
2022 Q1	$6.23M	Sell	183,017 -1,414	-0.8%	-$45.2K	﹤0.01%	1050
2021 Q4	$7.13M	Buy	+184,431	New	+$8.04M	﹤0.01%	975
2016 Q1	–	Sell	-4,133	Closed	-$972K	–	1305
2015 Q4	$972K	Hold	4,133	–	–	﹤0.01%	1115
2015 Q3	$653K	Buy	4,133 +682	+20%	+$193K	﹤0.01%	1182
2015 Q2	$1.31M	Sell	3,451 -1,130	-25%	-$449K	﹤0.01%	1104
2015 Q1	$1.92M	Sell	4,581 -974	-18%	-$348K	﹤0.01%	1057
2014 Q4	$1.52M	Sell	5,555 -9	-0.2%	-$2.24K	﹤0.01%	1132
2014 Q3	$1.08M	Buy	5,564 +1,402	+34%	+$305K	﹤0.01%	1169
2014 Q2	$1.02M	Sell	4,162 -738	-15%	-$167K	﹤0.01%	1213
2014 Q1	$1.3M	Sell	4,900 -117	-2%	-$44.8K	﹤0.01%	1176
2013 Q4	$1.82M	Sell	5,017 -13	-0.3%	-$5.01K	﹤0.01%	1128
2013 Q3	$2.67M	Buy	+5,030	New	+$1.72M	﹤0.01%	1054

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies's CLDX Position: Q2 2026 in Review

American Century Companies increased its Celldex Therapeutics (CLDX) stake by 22% in Q2 2026, buying an estimated $6.01M and bringing the position to 1,042,395 shares worth $38.8M. The position accounts for 0.02% of the portfolio, ranked #972.

American Century Companies first reported a position in CLDX in Q3 2013 and has held it in 29 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

American Century Companies held 1,042,395 shares of Celldex Therapeutics worth $38.8M as of Q2 2026.
American Century Companies bought 186,085 Celldex Therapeutics shares in Q2 2026, an estimated $6.01M.
Celldex Therapeutics made up 0.02% of American Century Companies's portfolio in Q2 2026, its #972 holding.
American Century Companies first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 29 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.